Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible

Area of Science:

• Pulmonary Medicine
• Drug Delivery Systems
• Oncology

Background:

• Lung cancer diagnosis often occurs at late stages, necessitating advanced treatment options.
• Non-small cell lung cancer benefits from novel therapies including tyrosine kinase inhibitors and immunotherapies.
• Current immunotherapies like pembrolizumab and nivolumab are used as first or second-line treatments, with ipilimumab under investigation.

Purpose of the Study:

• To evaluate the efficacy of aerosol treatment for lung cancer therapies.
• To determine the optimal design for aerosol delivery cups.
• To compare the particle size distribution of different immunotherapies.

Main Methods:

• Investigated aerosol treatment delivery for various diseases, focusing on lung applications.
• Compared different aerosol cup designs to assess their impact on droplet size.
• Analyzed the particle size characteristics (MMAD) of nivolumab, pembrolizumab, and ipilimumab.

Main Results:

• Aerosol cup design significantly impacts droplet size, with design J achieving the smallest mass median aerodynamic diameter (MMAD) of 1.99.
• Drug formulation is the second most significant factor, with nivolumab showing the smallest particle size (1.89).
• Droplet size decreased in the order: Ipilimumab > Pembrolizumab > Nivolumab.

Conclusions:

• Optimized aerosol cup design is crucial for effective drug delivery in lung cancer treatment.
• Specific immunotherapies exhibit varying particle size characteristics, influencing their delivery efficiency.
• Further research into aerosolized immunotherapies could improve lung cancer treatment outcomes.